What is large granular lymphocytic leukaemia?
Large granular lymphocytic leukaemia (LGL leukaemia) is a rare, usually slow-growing blood disorder. It affects large granular lymphocytes, a type of white blood cell that kills virus-infected and abnormal cells.
These cells get their name from the small granules inside them, which contain substances used to destroy target cells. In LGL leukaemia, one family of these cells keeps growing instead of dying off after an immune response.
The excess cells build up in the blood, bone marrow, spleen and liver. They often cause a low neutrophil count (neutropenia) and anaemia, and they are closely linked with autoimmune diseases, especially rheumatoid arthritis (Lamy, Moignet and Loughran, 2017).
Unlike most leukaemias, LGL leukaemia often behaves more like a chronic immune disorder than an aggressive cancer. Many people live for many years, and some never need treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Clonal growth of cytotoxic T cells or natural killer (NK) cells |
| How common | Rare; about 2-5% of chronic lymphoproliferative disorders in Western countries |
| Typical age | Median about 60; rare under 30 |
| Main types | T-cell LGL leukaemia (about 85%) and NK-cell LGL leukaemia (about 10%) |
| Key gene change | STAT3 mutations in about 40% (Koskela et al., 2012) |
| Main problems | Low neutrophils, anaemia, infections, rheumatoid arthritis |
| Main treatment | Methotrexate, cyclophosphamide or ciclosporin when treatment is needed |
| Outlook | Usually good; median survival over 10 years |
2. Types of LGL disorder
The World Health Organization classification recognises three related conditions (Alaggio et al., 2022):
| Type | Cell of origin | Behaviour |
|---|---|---|
| T-cell LGL leukaemia (T-LGLL) | Cytotoxic T cells, usually CD8-positive | Usually slow-growing; the most common form |
| NK-cell LGL leukaemia (NK-LGLL) | Natural killer cells | Usually slow-growing; very similar to T-LGLL |
| Aggressive NK-cell leukaemia | Natural killer cells, linked with Epstein-Barr virus | Rare, fast-growing and very serious; more common in Asia |
The sections below describe the slow-growing T-cell and NK-cell forms. Aggressive NK-cell leukaemia is a different disease that needs urgent intensive treatment.
3. Causes and risk factors
The exact cause of LGL leukaemia is not known. Experts think that long-term stimulation of the immune system, perhaps by an infection or by the body’s own tissues, drives a group of LGL cells to expand.
Over time, changes in the cells’ growth signals, especially the JAK-STAT pathway, allow them to escape normal control.
| Factor | Notes |
|---|---|
| STAT3 or STAT5B mutations | Found in the leukaemia cells; switch on survival signals |
| Rheumatoid arthritis | About 10-20% of people with T-LGLL have it |
| Other autoimmune diseases | Sjogren syndrome, lupus, autoimmune thyroid disease and others |
| Other blood disorders | Sometimes seen with B-cell lymphomas, MGUS or myelodysplastic syndromes |
| Organ or stem cell transplant | Short-lived LGL expansions can occur afterwards |
LGL leukaemia is not inherited and not infectious.
Link with Felty syndrome
Felty syndrome is a combination of rheumatoid arthritis, an enlarged spleen and neutropenia. It overlaps closely with T-LGLL, and some experts regard the two as part of the same disease spectrum.
4. How does it look
Under the microscope
In a blood film, LGL cells are larger than normal lymphocytes. They have a round or slightly kidney-shaped nucleus and plenty of pale blue cytoplasm, with scattered pink-purple (azurophilic) granules.
A healthy person has about 0.25 x 10^9/L of these cells in the blood. In LGL leukaemia, the count is often above 2 x 10^9/L. A count above 0.5 x 10^9/L that lasts for more than six months can still be diagnostic when other tests confirm that the cells are clonal.
Cell markers
| Type | Typical markers |
|---|---|
| T-LGLL | CD3+, CD8+, CD57+, CD16+, often CD5 weak; clonal T-cell receptor |
| NK-LGLL | CD3-, CD16+, CD56+; restricted KIR receptors |
Visible signs on the body
LGL leukaemia often causes few visible signs. Possible findings include:
| Sign | What it looks like |
|---|---|
| Pale skin | From anaemia |
| Mouth ulcers | Painful sores linked with low neutrophils |
| Skin infections | Boils, cellulitis or slow-healing wounds |
| Swollen abdomen | An enlarged spleen in about a quarter to half of patients |
| Swollen, deformed joints | From associated rheumatoid arthritis |
Swollen lymph nodes are uncommon in LGL leukaemia, which helps to distinguish it from many lymphomas.
5. Symptoms
About one-third of people have no symptoms when they are diagnosed. The condition is often discovered because a routine blood test shows low neutrophils, anaemia or a raised lymphocyte count.
Common symptoms
- Repeated infections, such as chest, skin, mouth or sinus infections
- Fever, sometimes with chills
- Mouth ulcers and sore gums
- Tiredness and breathlessness, from anaemia
- Discomfort or fullness in the upper left abdomen, from an enlarged spleen
- Night sweats and weight loss, in some people
- Joint pain, stiffness and swelling, if rheumatoid arthritis is present
Severe neutropenia
Neutrophils are the body’s main defence against bacteria. When the count falls below 0.5 x 10^9/L, the risk of serious infection rises sharply.
Pure red cell aplasia
In some people, LGL cells attack the bone marrow cells that make red blood cells. This is called pure red cell aplasia. It causes severe anaemia that can require regular blood transfusions.
When to seek medical advice
Seek urgent medical help if you have a fever of 38 C or more and know that your neutrophil count is low. This can be a sign of a serious infection that needs prompt antibiotics.
See your doctor if you have repeated infections, mouth ulcers, increasing tiredness or a full feeling in your abdomen.
6. Diagnosis
LGL leukaemia is diagnosed with blood tests and, in some cases, a bone marrow biopsy. International criteria have been developed to help doctors make the diagnosis consistently (Brammer et al., 2026).
| Test | Purpose |
|---|---|
| Full blood count and blood film | Shows neutropenia, anaemia and LGL cells |
| Flow cytometry | Counts LGL cells and checks their markers |
| T-cell receptor gene test | Confirms the T cells come from one clone |
| STAT3 and STAT5B mutation tests | Support the diagnosis |
| Bone marrow biopsy | Shows LGL cells in lines or clusters; checks for other causes |
| Ultrasound or CT scan | Measures the spleen and liver |
| Rheumatoid factor and other antibodies | Look for associated autoimmune disease |
| Virus tests | HIV, hepatitis and HTLV, which can cause similar blood changes |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Reactive LGL increase | Temporary, after infection or transplant; usually not clonal |
| T-cell prolymphocytic leukaemia | Faster-growing; usually CD4-positive with TCL1 changes |
| Hepatosplenic T-cell lymphoma | Aggressive; large spleen and liver in young people |
| Myelodysplastic syndromes | Bone marrow disease with abnormal-looking blood cells |
7. Treatment
When is treatment needed?
Many people only need regular blood tests. Treatment is usually started for (Lamy, Moignet and Loughran, 2017):
| Reason for treatment | Details |
|---|---|
| Severe neutropenia | Neutrophils below 0.5 x 10^9/L |
| Moderate neutropenia with infections | Neutrophils below 1.5 x 10^9/L and repeated infections |
| Symptomatic anaemia | Haemoglobin below about 100 g/L or needing transfusions |
| Associated autoimmune disease | Needing treatment, such as active rheumatoid arthritis |
| Troublesome symptoms | Such as a painful enlarged spleen or B symptoms |
First-line medicines
Treatment aims to calm the overactive LGL cells rather than to destroy every one. The main options are tablets given at low doses:
| Medicine | Usual use | Main points |
|---|---|---|
| Methotrexate | Low weekly dose; often first choice for neutropenia and arthritis | Folic acid given alongside; blood and liver tests |
| Cyclophosphamide | Daily tablet; often preferred for anaemia | Limited to a few months to reduce long-term risks |
| Ciclosporin | Twice-daily tablet | Kidney function and blood pressure checks |
A US trial showed that these medicines help many patients, but responses take time, often 2-4 months (Loughran et al., 2015). If one medicine does not work, another can be tried.
Other treatments
| Treatment | When it is used |
|---|---|
| G-CSF injections | To raise neutrophils during serious infections |
| Steroids | Short courses with other medicines; not effective alone |
| Splenectomy | Rarely, for a very large spleen or hard-to-treat disease |
| Ruxolitinib and other JAK inhibitors | Being studied for relapsed disease (Marchand et al., 2024) |
| Clinical trials | For people whose disease does not respond to standard medicines |
How response is measured
Doctors check blood counts every few weeks after starting treatment. A complete response means that blood counts return to normal and LGL cells fall back towards normal levels.
A partial response means that blood counts improve enough to reduce infections or transfusions. Even a partial response can make a big difference to everyday life, and treatment is often continued for at least a year if it is working.
Preventing infections
- Seek help early for fever or signs of infection
- Keep the mouth and teeth clean, and see a dentist regularly
- Wash hands often, and treat cuts promptly
- Have recommended vaccinations, such as flu and pneumonia vaccines
8. Outlook (prognosis)
Most people with slow-growing LGL leukaemia have a good outlook. The median survival is more than 10 years, and many people live a normal lifespan.
The main risks come from infections linked to neutropenia. With treatment and careful monitoring, these can usually be prevented or managed.
| Factor | Effect |
|---|---|
| No symptoms and stable counts | May never need treatment |
| Response to first treatment | Good long-term control |
| Severe neutropenia with infections | Needs active treatment; higher risk |
| Aggressive NK-cell leukaemia | Very different, serious outlook |
If treatment stops working
LGL leukaemia that comes back after treatment can usually be treated again. Doctors may restart the same medicine if it worked well before, or try one of the other first-line options.
For disease that does not respond to standard medicines, options include alemtuzumab, purine analogues such as pentostatin, splenectomy and clinical trials of JAK inhibitors and other targeted drugs.
9. Living with LGL leukaemia
LGL leukaemia is usually a long-term condition. You will have regular check-ups, often every 3-6 months when the disease is stable.
- Know your neutrophil count and when to seek urgent help
- Keep a thermometer at home
- Stay active and eat a balanced diet
- Tell other doctors and dentists about your condition
- Look after joint health if you have rheumatoid arthritis, working with your rheumatologist
Long-term follow-up
| Check | Why it is done |
|---|---|
| Blood counts | To watch neutrophils, haemoglobin and platelets |
| Liver and kidney tests | To check for side effects of methotrexate or ciclosporin |
| Blood pressure | Ciclosporin can raise it |
| Urine tests | Cyclophosphamide can irritate the bladder |
| Review of new symptoms | To pick up associated autoimmune or blood disorders early |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is LGL leukaemia cancer? | It is classified as a blood cancer, but it usually behaves like a chronic condition |
| Will I need chemotherapy? | If treatment is needed, it is usually low-dose tablets rather than intensive chemotherapy |
| Is it linked to my rheumatoid arthritis? | Possibly. The two conditions often occur together |
| Can it go away? | Treatment can bring long remissions, but the clone often persists at a low level |
| Is it inherited? | No |
| Can I have vaccines? | Most inactivated vaccines are recommended; live vaccines may need to be avoided during treatment |
| Will it turn into an aggressive leukaemia? | Transformation of slow-growing LGL leukaemia into an aggressive form is very rare |
11. Questions to ask your care team
- Do I have T-cell or NK-cell LGL leukaemia?
- Do I need treatment now, or can we monitor it?
- What neutrophil level should make me seek urgent help?
- Which medicine do you recommend, and how will we know it is working?
- How often will I need blood tests?
- Is my rheumatoid arthritis or other autoimmune condition linked, and who will manage it?
- What should I do if I get a fever or infection?
Resources
- Lamy, T., Moignet, A. and Loughran, T.P. (2017) ‘LGL leukemia: from pathogenesis to treatment’, Blood, 129(9), pp. 1082-1094.
- Koskela, H.L. et al. (2012) ‘Somatic STAT3 mutations in large granular lymphocytic leukemia’, New England Journal of Medicine, 366(20), pp. 1905-1913.
- Jerez, A. et al. (2012) ‘STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia’, Blood, 120(15), pp. 3048-3057.
- Loughran, T.P. et al. (2015) ‘Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)’, Leukemia, 29(4), pp. 886-894.
- Marchand, T. et al. (2024) ‘A modern view of LGL leukemia’, Blood, 144(18), pp. 1910-1923.
- Marchand, T. et al. (2024) ‘Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia’, British Journal of Haematology, 205(3), pp. 915-923.
- Brammer, J.E. et al. (2026) ‘International consensus criteria for the diagnosis, treatment initiation, and response assessment for T-LGL leukemia’, Blood.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Leukaemia Care (2026) About large granular lymphocytic leukaemia (LGLL). Available at: https://www.leukaemiacare.org.uk/about-leukaemia/types/large-granular-lymphocytic-leukaemia-lgll/about-large-granular-lymphocytic-leukaemia-lgll/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.